VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 45.5% in October

VanEck Biotech ETF (NASDAQ:BBH) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 600 shares, a decline of 45.5% from the October 15th total of 1,100 shares. Based on an average trading volume of 4,300 shares, the short-interest ratio is currently 0.1 days.

VanEck Biotech ETF Stock Down 4.4 %

Shares of BBH stock traded down $7.22 during trading on Friday, hitting $157.91. The company had a trading volume of 13,868 shares, compared to its average volume of 6,634. VanEck Biotech ETF has a 52 week low of $148.52 and a 52 week high of $183.64. The stock’s 50-day moving average is $175.32 and its two-hundred day moving average is $173.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BBH. Jane Street Group LLC boosted its position in shares of VanEck Biotech ETF by 401.7% during the third quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock valued at $1,481,000 after purchasing an additional 6,684 shares in the last quarter. Kovitz Investment Group Partners LLC increased its stake in shares of VanEck Biotech ETF by 4.6% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock worth $565,000 after acquiring an additional 141 shares in the last quarter. FSA Wealth Management LLC purchased a new position in VanEck Biotech ETF during the 3rd quarter valued at about $54,000. Truvestments Capital LLC purchased a new stake in VanEck Biotech ETF in the third quarter worth about $44,000. Finally, Coastline Trust Co purchased a new position in shares of VanEck Biotech ETF during the third quarter valued at approximately $59,000. 32.05% of the stock is owned by institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.